Former Shkreli-led drug developer pledges responsible pricing

(Reuters) - A biotechnology company, previously led by controversial former drug executive Martin Shkreli, on Monday vowed not to engage in aggressive pricing and to develop a transparent and 'responsible' pricing model for its products.